

Curriculum Vitae

Dr. Kishore Parsa

Senior Principal Research Scientist,

Head-Center for Innovation and Molecular Pharmaceutical Sciences

Dr. Reddy's Institute of Life Sciences, Hyderabad

kishorep@drils.org; kparsa@gmail.com

Phone: +91 (40) 66571527; 9908800014

Fax: +91 (40) 66571581

Education

S. No.	Institution Place	Degree Awarded	Year	Field of Study
1	The Ohio State University, USA	Ph.D.	2007	Biochemistry
2	Texas A&M University-Kingsville, USA	M.S.	2004	Biochemistry
3	Acharya NG Ranga Agricultural University, Hyderabad, India	M.V.Sc.	2001	Animal Genetics and Breeding
4	Acharya NG Ranga Agricultural University, Hyderabad, India	B.V.Sc.	1999	Veterinary Sciences

Position and Honours

Position and Employment (Starting with the most recent employment)

S. No.	Institution Place	Position	From (Date)	To (date)
1	Dr. Reddy's Institute of Life Sciences, Hyderabad	Senior Principal Research Scientist and Head- Center for Innovation in Molecular and Pharmaceutical Sciences	April 1st 2021	To date
2	Dr. Reddy's Institute of Life Sciences, Hyderabad	Principal Research Scientist Head-CIMPS	September 2018	March 31st 2021
3	Dr. Reddy's Institute of Life Sciences, Hyderabad	Principal Research Scientist and Head of the Department-Biology	July 2016	September 2018

3	Dr. Reddy's Institute of Life Sciences, Hyderabad	Principal Research Scientist	2013	2016
4	Institute of Life Sciences, Hyderabad	Senior Research Scientist	2009	2012
5	Matrix Laboratories Ltd, Hyderabad	Assistant Manager	2008	2009

Honours/Awards

- 2001 Prize for second best poster at Texas Academy of Sciences, USA
- 2001-04 Welch scholarship at Texas A&M University-Kingsville, USA
- 2001-04 Research Assistantship at Texas A&M University-Kingsville, USA
- 2003-04 Teaching Assistantship at Texas A&M University-Kingsville, USA
- 2004-05 Program fellowship at The Ohio State University, USA
- 2005-07 Research Assistantship at The Ohio State University, USA
- 2007 Best poster award, IGP first annual symposium, USA
- 2011 Department of Atomic Energy Young Scientist Award (Basic Sciences), Mumbai, India
- 2014-2021 Member, Medical Biotechnology-Infectious Diseases Technical Evaluation Committee, Department of Biotechnology
- 2018- Member, Royal Society of Biology
- 2023- Member, Scientific Review Committee of Asian Health care Foundation, Asian Institute of Gastroenterology

Number of researchers trained: Associate Scientists: 2; Post-docs: 8; PhD 8 as a guide (two under training) and 4 as a co-guide (2 under training); Bachelor of Dental Surgery: 1; Master of Pharmacy: 5; Master of Science: 10; Master of Technology: 3; Bachelor of Technology: 3; Research Trainees: 12

Research Papers: 67; (h-index: 26; i-10 index: 53; total number of citations: 2349)

Patents awarded: 1

Selected articles:

1. TGS1/PIMT regulates pro-inflammatory macrophage mediated paracrine insulin resistance: Crosstalk between macrophages and skeletal muscle cells. Challa NL, Sarkar A, Kapettu S, Phanithi PB, Chakrabarti P, **Parsa KVL***, Misra P*. Biochim Biophys Acta Mol Basis Dis. 2023 Sep 4;1870(1):166878. doi: 10.1016/j.bbadis.2023.166878.

***Corresponding author**

2. TGS1/PIMT knockdown reduces lipid accumulation in adipocytes, limits body weight gain and promotes insulin sensitivity in mice. Edwin RK, Acharya LP, Maity SK, Chakrabarti P, Tantia O, Joshi MB, Satyamoorthy K, Parsa KVL*, Misra P*. *Biochim Biophys Acta Mol Basis Dis.* 2023 Sep 24;1870(1):166896. doi: 10.1016/j.bbadis.2023.166896. ***Corresponding author**
3. Sharma R, Maity SK, Chakrabarti P, Katika MR, Kapettu S, Parsa KVL*, Misra P*. PIMT Controls Insulin Synthesis and Secretion through PDX1. *Int J Mol Sci.* 2023 Apr 29;24(9):8084. doi: 10.3390/ijms24098084. ***Corresponding author**
4. Chandra K, Swathi M, Keerthana B, Gopan S, Ghantasala JP, Joshi MB, Thondamal M, Parsa KVL*. PHLPP1 regulates PINK1-parkin signalling and life span. *Biochim Biophys Acta Mol Basis Dis.* 2023 Apr 13:166718. doi: 10.1016/j.bbadis.2023.166718
5. Kapadia B, Behera S, Kumar ST, Shah T, Edwin RK, Babu PP, Chakrabarti P, Parsa KVL*, Misra P*. PIMT regulates hepatic gluconeogenesis in mice. *iScience.* 2023 Feb 2;26(3):106120. doi: 10.1016/j.isci.2023.106120 ***Corresponding author**
6. Balamurugan K, Medishetti R, Rao P, K RV, Chatti K*, Parsa KVL*. Protocol to evaluate hyperlipidemia in zebrafish larvae. *STAR Protoc.* 2022 Nov 7;3(4):101819. doi: 10.1016/j.xpro.2022.101819. ***Corresponding author**
7. Medishetti R, Balamurugan K, Yadavalli K, Rani R, Sevilimedu A, Challa AK, Parsa K, Chatti K. CRISPR-Cas9-induced gene knockout in zebrafish. *STAR Protoc.* 2022 Oct 26;3(4):101779. doi: 10.1016/j.xpro.2022.101779.
8. Balamurugan K, Chandra K, Sai Latha S, Swathi M, Joshi MB, Misra P, Parsa KVL*. PHLPPs: Emerging players in metabolic disorders. *Drug Discov Today* 2022. ***Corresponding author**
9. Edwin RK, Challa N, Sharma R, Satyamoorthy K, Parsa K*, Misra P*. PIMT/TGS1: An evolving metabolic molecular switch with conserved methyl transferase activity. *Drug Discov Today* 2022. ***Corresponding author**
10. Balamurugan K, Medishetti R, Kotha J, Behera P, Chandra K, Mavuduru VA, Joshi MB, Samineni R, Katika MR, Ball WB, Thondamal M, Challa A, Chatti K*, Parsa KVL*. (2022). PHLPP1 promotes neutral lipid accumulation through AMPK/ChREBP-dependent lipid uptake and fatty acid synthesis pathways. *iScience.* 2022. ***Corresponding author**
11. Rani R, Parsa KVL, Chatti K, Sevilimedu A. An efficient and cost-effective method for directed mutagenesis at multiple dispersed sites-a case study with Omicron Spike DNA. *Biol Methods Protoc.* 2022 Dec 22;8(1):bpac037. doi: 10.1093/biomethods/bpac037.
12. Sunke, R., Bankala, R., Thirupataiah, B., Ramarao, E., Kumar, J. S., Doss, H. M., Medishetti, R., Kulkarni, P., Kapavarapu, R. K., Rasool, M., Mudgal, J., Mathew, J. E., Shenoy, G. G., Parsa, K. V. L*, and Pal, M*. (2019) InCl₃ mediated heteroarylation of indoles and their derivatization via CH activation strategy: Discovery of 2-(1H-indol-3-yl)-quinoxaline derivatives as a new class of PDE4B selective inhibitors for arthritis and/or multiple sclerosis. *Eur J Med Chem* 174, 198-215 ***Corresponding author**
13. Behera S, Kapadia B, Kain V, Alamuru-Yellapragada NP, Murunikkara V, Kumar ST, Babu PP, Seshadri S, Shivarudraiah P, Hiriyana J, Gangula NR, Maddika S, Misra P, Parsa KVL*. (2018) ERK1/2 activated PHLPP1 induces skeletal muscle ER stress through the inhibition of a novel substrate AMPK. *Biochim Biophys Acta.* 2018; 1864, 1702-1716. ***Corresponding author**

14. Bung, N., Surepalli, S., Seshadri, S., Patel, S., Peddasomayajula, S., Kummari, L. K., Kumar, S. T., Babu, P. P., Parsa, K. V. L., Poondra, R. R., Bulusu, G., and Misra, P. (2018) 2-[2-(4-(trifluoromethyl)phenylamino)thiazol-4-yl]acetic acid (Activator-3) is a potent activator of AMPK. *Scientific reports* 8, 9599
15. Talari M, Nayak TK, Kain V, Babu PP, Misra P, Parsa KV* (2017) MicroRNA-712 restrains macrophage pro-inflammatory responses by targeting LRRK2 leading to restoration of insulin stimulated glucose uptake by myoblasts. *Mol Immunol.* 82, 1-9. *Corresponding author
16. Alamuru-Yellapragada NP, Vundyala S, Behera S, Parsa KV*. (2017) LPS depletes PHLPP levels in macrophages through the inhibition of SP1 dependent transcriptional regulation. *Biochem Biophys Res Commun* 486, 533-538 *Corresponding author
17. Nayak, TKS; Alamuru-Yellapragada, NP; Parsa KV* (2017) Deubiquitinase USP12 promotes LPS induced macrophage responses through inhibition of I κ B α . *Biochem Biophys Res Commun.* 483(1), 69-74. *Corresponding author
18. Kain, V., Kapadia, B., Viswakarma, N., Seshadri, S., Prajapati, B., Jena, P. K., Teja Meda, C. L., Subramanian, M., Kaimal Suraj, S., Kumar, S. T., Prakash Babu, P., Thimmapaya, B., Reddy, J. K., Parsa, K. V*, and Misra, P*. (2015) Co-activator binding protein PIMT mediates TNF- α induced insulin resistance in skeletal muscle via the transcriptional down-regulation of MEF2A and GLUT4. *Scientific reports* 5, 15197. *Corresponding author
19. Talari, M., Kapadia, B., Kain, V., Seshadri, S., Prajapati, B., Rajput, P., Misra, P., and Parsa, K. V*. (2015) MicroRNA-16 modulates macrophage polarization leading to improved insulin sensitivity in myoblasts. *Biochimie* 119, 16-26. *Corresponding author
20. Alamuru, N. P., Behera, S., Butchar, J. P., Tridandapani, S., Kaimal Suraj, S., Babu, P. P., Hasnain, S. E., Ehtesham, N. Z., and Parsa, K. V. (2014) A novel immunomodulatory function of PHLPP1: inhibition of iNOS via attenuation of STAT1 ser⁷²⁷ phosphorylation in mouse macrophages. *J Leukoc Biol.* 95, 775-783 *Corresponding author
21. Bandish Kapadia, Navin Viswakarma, Kishore VL Parsa, Vasundhara Kain, Soma Behera, Sasidhara Kaimal Suraj, P. Prakash Babu, Anand Kar, Sunanda Panda, Yi-jun Zhu, Yuzhi Jia, Bayar Thimmapaya, Janardan K. Reddy and Parimal Misra. (2013) ERK2-mediated phosphorylation of transcriptional coactivator binding protein PIMT/NCoA6IP at Ser²⁹⁸ augments hepatic gluconeogenesis. *PLoS One* Dec 17;8(12):e83787.
22. Sunke, R., Adepu, R., Kapavarapu, R., Chintala, S., Meda, C.L., Parsa, K.V., and Pal, M. (2013) Vinylic amino group activation: a new and general strategy leading to functionalized fused heteroaromatics. *Chem Commun (Camb)* 49, 3570-3572.
23. Gorja, D.R., Mukherjee, S., Meda, C.L., Deora, G.S., Lalith Kumar, K., Jain, A., Chaudhari, G.H., Chennubhotla, K.S., Banote, R.K., Kulkarni, P., Parsa, K.V*, Mukkanti, K., and Pal, M*. (2013) Novel N-indolylmethyl substituted olanzapine derivatives: their design, synthesis and evaluation as PDE4B inhibitors. *Org Biomol Chem* 2013 11, 2075-2079. *Equal senior and co-corresponding authorship
24. Reddy, S.V., Rao, G.M., Kumar, B.V., Meda, C.L., Deora, G.S., Kumar, K.S., Parsa, K.V., and Pal, M. (2013) Novel imidazophenoxazine-4-sulfonamides: Their synthesis and evaluation as potential inhibitors of PDE4. *Bioorg Med Chem* 21, 1952-1963.

25. Reddy, T.R., Reddy, G.R., Reddy, L.S., Meda, C.L., Parsa, K.V., Kumar, K.S., Lingappa, Y., and Pal, M. (2013) Montmorillonite K-10 catalyzed green synthesis of 2,6-unsubstituted dihydropyridines as potential inhibitors of PDE4. *Eur J Med Chem* 62C, 395-404.
26. Poondra, R.R*, Nallamelli, R.V., Meda, C.L., Srinivas, B.N., Grover, A., Muttabathula, J., Voleti, S.R., Sridhar, B., Pal, M., and Parsa, K.V*. Discovery of novel 1,4-dihydropyridine-based PDE4 inhibitors. (2013) *Bioorg Med Chem Lett* 23, 1104-1109. **Equal senior and co-corresponding authorship**
27. Adepu, R., Sunke, R., Meda, C.L., Rambabu, D., Krishna, G.R., Reddy, C.M., Deora, G.S., Parsa, K.V., and Pal, M. Facile assembly of two 6-membered fused N-heterocyclic rings: a rapid access to novel small molecules via Cu-mediated reaction. (2013) *Chem Commun (Camb)* 49, 190-192.
28. Nakhi, A., Rahman, M.S., Kishore, R., Meda, C.L., Deora, G.S., Parsa, K.V., and Pal, M. (2012). Pyrrolo[2,3-b]quinoxalines as inhibitors of firefly luciferase: Their Cu-mediated synthesis and evaluation as false positives in a reporter gene assay. *Bioorg Med Chem Lett* 22, 6433-6441.
29. Bhaskar Kumar, T., Sumanth, C., Vaishaly, S., Srinivasa Rao, M., Chandra Sekhar, K.B., Meda, C.L., Kandale, A., Rambabu, D., Rama Krishna, G., Malla Reddy, C., Shiva Kumar, K., Parsa, K.V., and Pal, M. (2012). Pd-mediated functionalization of polysubstituted pyrroles: Their evaluation as potential inhibitors of PDE4. *Bioorg Med Chem Lett* 22, 5639-5647.
30. Adepu, R., Rambabu, D., Prasad, B., Meda, C.L., Kandale, A., Krishna, G.R., Reddy, C.M., Chennuru, L.N., Parsa, K.V*, and Pal, M*. (2012). Novel thieno[2,3-d]pyrimidines: their design, synthesis, crystal structure analysis and pharmacological evaluation. *Org Biomol Chem* 10, 5554-5569. *, **Equal senior and co-corresponding authorship**
31. Reddy, T.S., Kumar, K.S., Meda, C.L., Kandale, A., Rambabu, D., Krishna, G.R., Hariprasad, C., Rao, V.V., Venkataiah, S., Reddy, C.M., Naidu, A., Dubey, P.K., Parsa, K.V., and Pal, M. (2012). Conformationally restricted novel pyrazole derivatives: synthesis of 1,8-disubstituted 5,5-dimethyl-4,5-dihydro-1H-benzo[g]indazoles as a new class of PDE4 inhibitors. *Bioorg Med Chem Lett* 22, 3248-3255.
32. Kumar, K.S., Kumar, P.M., Rao, V.S., Jafar, A.A., Meda, C.L., Kapavarapu, R., Parsa, K.V., and Pal, M. (2012). A new cascade reaction: concurrent construction of six and five membered rings leading to novel fused quinazolinones. *Org Biomol Chem* 10, 3098-3103.
33. Kumar, K.S., Kiran Kumar, S., Yogi Sreenivas, B., Gorja, D.R., Kapavarapu, R., Rambabu, D., Rama Krishna, G., Reddy, C.M., Basaveswara Rao, M.V., Parsa, K.V., and Pal, M. (2012). C-C bond formation at C-2 of a quinoline ring: synthesis of 2-(1H-indol-3-yl)quinoline-3-carbonitrile derivatives as a new class of PDE4 inhibitors. *Bioorg Med Chem* 20, 2199-2207.
34. Gorja, D.R., Shiva Kumar, K., Kandale, A., Meda, C.L., Parsa, K.V., Mukkanti, K., and Pal, M. (2012). Design and synthesis of 4-alkynyl pyrazoles as inhibitors of PDE4: a practical access via Pd/C-Cu catalysis. *Bioorg Med Chem Lett* 22, 2480-2487.
35. Ram Reddy, T., Rajeshwar Reddy, G., Srinivasula Reddy, L., Jammula, S., Lingappa, Y., Kapavarapu, R., Meda, C.L., Parsa, K.V., and Pal, M. (2012). Montmorillonite K-10

mediated green synthesis of cyano pyridines: Their evaluation as potential inhibitors of PDE4. *Eur J Med Chem* 48, 265-274.

36. Kumar, P.M., Kumar, K.S., Mohakud, P.K., Mukkanti, K., Kapavarapu, R., **Parsa, K.V.**, and Pal, M. (2012). Construction of a six-membered fused N-heterocyclic ring via a new 3-component reaction: synthesis of (pyrazolo)pyrimidines/pyridines. *Chem Commun (Camb)* 48, 431-433.
37. Mahesh Kumar, P., Siva Kumar, K., Meda, C.L.T., Rajeshwar Reddy, G., Mohakud, P.K., Mukkanti, K., Rama Krishna, G., Malla Reddy, C., Rambabu, D., Shiva Kumar, K., Krishna Priya, K., Chennubhotla, K.S., Banote, R.K., Kulkarni, P., **Parsa, K.V.L.***, and Pal, M*. (2012). (Pd/C-mediated) coupling-iodocyclization-coupling strategy in discovery of novel PDE4 inhibitors: a new synthesis of pyrazolopyrimidines. *MedChemComm* 3, 667-672. *, **Equal senior and co-corresponding authorship**
38. **Parsa, K.V.**, and Pal, M. (2011). Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview. *Expert Opin Drug Discov* 6, 855-869.
39. Pal, S., Durgadas, S., Nallapati, S.B., Mukkanti, K., Kapavarapu, R., Meda, C.L., **Parsa, K.V.**, and Pal, M. (2011). Novel 1-alkynyl substituted 1,2-dihydroquinoline derivatives from nimesulide (and their 2-oxo analogues): a new strategy to identify inhibitors of PDE4B. *Bioorg Med Chem Lett* 21, 6573-6576.
40. Reddy, G.R., Reddy, T.R., Joseph, S.C., Reddy, K.S., Reddy, L.S., Kumar, P.M., Krishna, G.R., Reddy, C.M., Rambabu, D., Kapavarapu, R., Lakshmi, C., Meda, T., Priya, K.K., **Parsa, K.V.**, and Pal, M. (2011). Pd-mediated new synthesis of pyrroles: their evaluation as potential inhibitors of phosphodiesterase 4. *Chem Commun (Camb)* 47, 7779-7781.
41. Kumar, K.S., Kumar, P.M., Kumar, K.A., Sreenivasulu, M., Jafar, A.A., Rambabu, D., Krishna, G.R., Reddy, C.M., Kapavarapu, R., Shivakumar, K., Priya, K.K., **Parsa, K.V.**, and Pal, M. (2011). A new three-component reaction: green synthesis of novel isoindolo[2,1-a]quinazoline derivatives as potent inhibitors of TNF-alpha. *Chem Commun (Camb)* 47, 5010-5012.
42. Malladi, S.[#] **Parsa, K.V.[#]**, Bhupathi, D., Rodriguez-Gonzalez, M.A., Conde, J.A., Anumula, P., Romo, H.E., Claunch, C.J., Ballester, R.P., and Gonzalez-Garcia, M. (2011). Deletion mutational analysis of BMRP, a pro-apoptotic protein that binds to Bcl-2. *Mol Cell Biochem* 351, 217-232. [#] **Equal first authorship**
43. **Parsa KV**, Butchar JP, Rajaram MV, Gunn JS, Schlesinger, LS and Tridandapani, S. (2008) *Francisella* gains a survival advantage within mononuclear phagocytes by suppressing host IFN γ response. *Mol. Immunol.* 45(12):3428-37.
44. Rajaram MV, Butchar JP, **Parsa KV**, Cremer JT et al. (2009) Akt and SHIP modulate *Francisella* escape from the phagosome and induction of the Fas-mediated death pathway. *PLoS One.* 4(11):e7919.
45. **Parsa KV**, Butchar JP, Rajaram MV, Cremer JT and Tridandapani, S. (2008) The Tyrosine kinase Syk promotes the phagocytosis of *Francisella* through the activation of Erk. *Mol. Immunol.* 45(10):3012-21.
46. Butchar JP, **Parsa KV**, Marsh CB and Tridandapani S. (2008) IFN gamma enhances IL-23 production during *Francisella* infection of human monocytes. *FEBS Lett.* 582(7):1044-8.

47. Henning, LN, Azad, AK, Parsa KV, Crowther, JE, Tridandapani, S, and Schlesinger, LS. (2008) Pulmonary surfactant protein A regulates TLR expression and activity in human macrophages. *J Immunol.* 180(12):7847-58.
48. Butchar JP, Rajaram MV, Ganesan LP, Parsa KV, Clay CD, Schlesinger, LS, Tridandapani, S. (2007) *Francisella tularensis* induces IL-23 production in human monocytes. *J. Immunol.*;178:4445-4454.
49. Parsa KV, Ganesan LP, Rajaram MV et al. (2006) Macrophage pro-inflammatory response to *Francisella novicida* infection is regulated by SHIP. *PLoS Pathog.*;2:e71
50. Butchar JP, Parsa KV, Marsh CB and Tridandapani S. (2006) Negative regulators of Toll-like receptor 4-mediated macrophage inflammatory response. *Current Pharmaceutical Design* (32):4143-53.
51. Rajaram MV, Ganesan LP, Parsa KV et al. (2006) Akt/Protein kinase B modulates macrophage inflammatory response to *Francisella* infection and confers a survival advantage in mice. *J Immunol.* 177:6317-6324.
52. Chintharlapalli SR, Jasti M, Malladi S, Parsa KV, Ballesteros R.P. and Gonzalez-Garcia, M. (2005) BMRP is a Bcl-2 binding protein that induces apoptosis. *J. Cell.* 94(3):611-26.
53. Vancha AR, Govindaraju S, Parsa KV, Gonzalez-Garcia M, Ballesteros R.P. (2004) Use of polyethyleneimine polymer in cell culture as attachment factor and lipofection enhancer, *BMC Biotechnol.*, 4(1):23

Research Support

Ongoing Research Projects:

Sr.No.	Title	Cost (in rupees)	Duration	Agency
Dr. Kishore Parsa's Ongoing projects (AS-PI)				
1	Functional Analysis of PHLPP1 in Myogenesis: Implications for skeletal muscle dystrophies	90,86,720	12/01/2022 to 11/01/2025	DBT (As PI)
Dr. Kishore Parsa's Ongoing projects (AS-Co-PI)				
1	Understanding the regulatory role of co-activator binding protein PIMT in the pancreatic β -cells of diabetic animals and T3C diabetic (acute pancreatitis) humans	69,44,000	31-12- 2021 to 30-12-2024	SERB, India (As Co-PI)

2	A pre-clinical lead optimization study of adjunct medicaments for reducing duration and increasing efficacy of anti-tuberculosis drug therapy	1,99,98,000	12/12/2022 to 11/2/2025	DBT (As 2nd Co-PI)
---	---	-------------	-------------------------	--------------------

Completed Research Projects:

Sr.No.	Title	Cost (in rupees)	Duration	Agency
Dr. Kishore Parsa's completed projects (AS-PI)				
1	Molecular characterization of the functional role of ser/thr phosphatase PHLPP in pancreatic beta cells to gain mechanistic insights into diabetes	52,94,004	27/02/2020 to 26/02/2023	SERB (As PI)
2	Molecular analysis of the functional role of ser/thr phosphatase PHLPP in lipid induced formation of foam cells, a hallmark of atherosclerosis	49,99,300	29/1/2019 to 28/1/2022	DBT (As PI)
3	Understanding the functional role of ser/thr phosphatase PHLPP in inflammation/ER stress induced insulin resistance in skeletal muscle	72,01,187	16/11/2017 to 15/11/2020	DBT (As PI)
4	Investigation of the regulatory role of miR-712 in inflammation induced skeletal muscle insulin resistance	53,64,000	19/7/2016 to 18/7/2019	SERB (As PI)
5	Elucidation of PHLPP1 signaling during macrophage activation: Requirement of domains and identification of stimulus specific interaction partners	28,84,800	01/01/2015-31/1/2018	CSIR (As PI)
5	Molecular analysis of the functional role of macrophage microRNA in regulating insulin resistance (SR/FT/LS-131/2009)	20,64,000	02/07/12-01/07/15	DST (As PI)

6	Understanding the role of PHLPP in IFN γ -mediated innate immune responses (BT/PR14123/Med/29/193/2010)	58,20,000	07/10/10-06/10/13	DBT (As PI)
7	Molecular analysis of the role of PHLPP1 in LPS-induced macrophage inflammatory response	12,60,000	28/01/10-31/1/14	CSIR (As PI)
8	Identification of novel Akt-interacting partners and investigation of their role in LPS-induced macrophage inflammatory response	13,20,000	01/04/11-31/03/14	DAE (As PI)
Dr. Kishore Parsa's completed projects (AS-Co-PI)				
1	Understanding the functional role of co-activator binding protein in adipogenesis and obesity	64,21,533	11/03/2020 to 10/03/2023	DBT (As Co-PI)
2	Potent and selective PDE4B inhibitors for the potential treatment of arthritis.	58,01,800	13/08/18-12/08/2021	DBT (As Co-PI)
3	Understanding the functional role of co-activator binding protein PIMT in myogenesis	68,46,800	27/03/2017-26/03/2020	SERB (As Co-PI)
4	Design and development of novel phosphodiesterase (PDE4) inhibitors	37,66,800	29/09/2014-28/09/2016	DBT (As Co-PI)
5	Understanding the role of transcriptional co-activator binding protein PIMT in the control of hepatic gluconeogenesis	60,20,000	01/07/11-31/01/15	DBT (As Co-PI)
6	Design, synthesis and identification of phosphodiesterase 4 (PDE4) inhibitors possessing improved safety profile (BT/PR12829/Med/30/222/2009)	24,99,000	05/05/2010-05/05/2011	DBT (As co-PI)